Your browser doesn't support javascript.
loading
Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder.
Rafizadeh, Reza; Sooch, Anmol; Risi, Alessia; Bihelek, Nicoline; Kanegawa, Kyler; Barr, Alasdair M; White, Randall F; Schütz, Christian G; Bousman, Chad A.
Afiliação
  • Rafizadeh R; Department of Experimental Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Sooch A; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • Risi A; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Bihelek N; BC Mental Health and Substance Use Services, Vancouver, BC, Canada.
  • Kanegawa K; BC Psychosis Program, UBC Hospital, Vancouver, BC, Canada.
  • Barr AM; Lower Mainland Pharmacy Services, Vancouver, BC, Canada.
  • White RF; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Schütz CG; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Bousman CA; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
J Psychopharmacol ; 38(6): 526-531, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38520287
ABSTRACT

BACKGROUND:

There is high inter-individual variability in clozapine metabolism due to genetic and non-genetic differences. Patient-specific factors such as smoking, inflammation indicated by elevated C-reactive protein (CRP), and certain concurrent medications have a significant influence on clozapine metabolism.

AIM:

To assess which patient-specific factors best explain variability in clozapine metabolism estimated by clozapine concentration to dose (C/D) ratios.

METHODS:

A retrospective cohort analysis using electronic medical data was conducted on 172 inpatients at the BC Psychosis Program. Patients with normal renal and liver function were included if they were on clozapine and had at least one steady-state plasma concentration. The degree of influence of each factor on the variability of clozapine metabolism in the entire cohort and subgroups stratified by fluvoxamine use was evaluated using multiple linear regression analysis of C/D ratios.

RESULTS:

Model fit testing showed that the entire cohort model accounts for 52.7% of C/D ratio variability, while the no fluvoxamine and fluvoxamine models accounted for 40.8% and 43.8%. In the entire cohort (n = 172), fluvoxamine use explained the highest variance, and C/D ratios were higher by 30.6% on average. The second strongest predictor was elevated CRP > 10 mg/L, and C/D ratios were higher by 22.9% on average. Subsequently, obesity, nonsmoker status, and female sex explained a significant but modest proportion of variance. Among participants on fluvoxamine (n = 58), only fluvoxamine dose was associated with an increase, and for every 25 mg increase in dose, C/D ratios increased by 5% on average.

CONCLUSION:

In a clinical population, this study replicated the relationship between reduced rate of clozapine metabolism and the use of fluvoxamine, elevated CRP, obesity, nonsmoking status, and female sex; and the magnitude of the effects were large enough to be clinically relevant.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Antipsicóticos / Fluvoxamina / Clozapina / Esquizofrenia Resistente ao Tratamento Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Antipsicóticos / Fluvoxamina / Clozapina / Esquizofrenia Resistente ao Tratamento Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article